• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » January 2011 – The CenterWatch Monthly : PDF
January 2011 – The CenterWatch Monthly : PDF

January 2011 – The CenterWatch Monthly : PDF

$79.00

Product Details

Another Wave of U.S. Site Acquisition Imminent

Experienced, U.S.-based investigative sites may remember the mid-to-late 1990s, when venture-backed companies were on a buying spree to build site management organizations (SMOs). That era may seem long gone, but signs now point to a new wave of acquisitions and consolidation looming. And this new wave may very well be driven by the most unlikely of sources: large European SMOs.

Are IRBs Ripe for an Overhaul?

As frustration with the expansive mission and bureaucracy of Institutional Review Boards (IRBs) builds, it has become clear that the current system for protecting research subjects needs a radical overhaul. But the system has evolved throughout the years into a complex web of agencies with differing agendas, which makes significant change unlikely without some type of federal mandate to critically evaluate the system or the development of a centralized oversight process.

Eye On Gilead

The stated mission of Gilead Sciences is to discover, develop and market novel therapeutic drugs in areas of unmet need that will improve care for patients with life-threatening illnesses. Specifically, Gilead aims to develop agents that are significant advancements over currently available products because of improved modes of delivery, more patient-friendly treatment regimens and fewer adverse effects promoting compliance, better resistance profiles, and greater efficacy.

Also in this issue:

  • Latino Recruitment: Tailor Your Approach to Reach Goals
  • How to Budget for Your Site
  • 2010 Year in Review
  • The Pulse on Recruitment
  • TrialWatch
  • New Study Launches
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing